These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 25503113)

  • 1. Transcatheter arterial embolic therapies for hepatocellular carcinoma: a literature review.
    Nishikawa H; Kita R; Kimura T; Osaki Y
    Anticancer Res; 2014 Dec; 34(12):6877-86. PubMed ID: 25503113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC.
    Koizumi Y; Hirooka M; Uehara T; Kisaka Y; Uesugi K; Kumagi T; Abe M; Matsuura B; Hiasa Y; Onji M
    Hepatogastroenterology; 2011; 58(106):512-5. PubMed ID: 21661422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma.
    Nishikawa H; Osaki Y; Kita R; Kimura T; Ohara Y; Takeda H; Sakamoto A; Saito S; Nishijima N; Nasu A; Komekado H; Nishiguchi S
    Oncol Rep; 2014 Jan; 31(1):65-72. PubMed ID: 24220763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 9. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
    Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
    Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
    Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE).
    Wiggermann P; Sieron D; Brosche C; Brauer T; Scheer F; Platzek I; Wawrzynek W; Stroszczynski C
    Med Sci Monit; 2011 Apr; 17(4):CR189-95. PubMed ID: 21455104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
    Seki A; Hori S
    Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review.
    Idée JM; Guiu B
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):530-49. PubMed ID: 23921081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art.
    Facciorusso A
    World J Gastroenterol; 2018 Jan; 24(2):161-169. PubMed ID: 29375202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
    Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
    Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents.
    Brown DB; Pilgram TK; Darcy MD; Fundakowski CE; Lisker-Melman M; Chapman WC; Crippin JS
    J Vasc Interv Radiol; 2005 Dec; 16(12):1661-6. PubMed ID: 16371533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
    Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
    Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
    Imai N; Ikeda K; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.